Craven House Capital Regulatory News (CRV)

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF REGULATION (EU) 596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EU (WITHDRAWAL) ACT 2018. 

Craven House Capital plc

("Craven House" or the "Company")

Investee company update: Bio Vitos

The Board of Craven House notes the announcement released earlier today by Hemcheck Sweden AB ("Hemcheck"). Further to its investee company update released at 7:00AM on 8 February 2023, which outlined that its investee company Bio Vitos was being acquired in a share exchange transaction by Nasdaq listed Hemcheck, Craven House now announces that whilst the acquisition by Hemcheck has now been completed and approved by Hemcheck shareholders, the prior approval application submitted to Nasdaq Stockholm, by Hemcheck, has not been approved by Nasdaq. Hemcheck and Bio Vitos have therefore entered into a supplementary agreement that will enable current operations to remain in operation whilst an updated re-listing application is submitted by Hemcheck to Nasdaq.

Bio Vitos anticipates that it will receive its shares in Hemcheck before the end of July 2023 which will be passed directly onto the Bio Vitos shareholders, which include Craven House. Craven House's 24.5% holding in Bio Vitos, will remain unchanged. 

Further announcements will be made in due course as appropriate. 

For further information please contact:

About Craven House Capital:

The Company's Investing Policy is primarily to invest in or acquire a portfolio of companies, partnerships, joint ventures, businesses or other assets participating in the e-Commerce sector.